RNA Polymerase I Complex as A Drug Target and Biomarker (P47495)

Target Name: RNA Polymerase I Complex

NCBI ID: P47495

RNA Polymerase I Complex

Other Name(s): Pol I

RNA Polymerase I Complex as A Drug Target and Biomarker

RNA polymerase I complex (Pol I) is a protein that plays a crucial role in the process of transcription in the cell. It is a complex protein that consists of multiple subunits that are responsible for catalyzing the synthesis of RNA from DNA template. Pol I is composed of two main subunits, pol I alpha and pol I beta, which work together to initiate the transcription process.

Pol I alpha is the primary subunit of Pol I and is responsible for the initiation of the transcription process. It has a characteristic alpha-helices structure that is composed of several conserved helices. These helices are important for the stability and function of the alpha subunit , and they play a crucial role in the regulation of the transcription process.

Pol I beta is the second subunit of Pol I and is responsible for the extension of the DNA template. It has a beta-sheet structure and is composed of several conserved regions, including a core alpha-helices region, a beta-helices region, and a terminal region that includes a leucine-rich repeat (LRR) and a glycine-rich repeat (GSR) domains. These regions are important for the stability and function of the beta subunit, and they play a crucial role in the regulation of the transcription process.

The Pol I complex is involved in the regulation of gene expression by controlling the access to the DNA template and by regulating the rate of transcription elongation. It is known that Pol I is involved in the regulation of gene expression by controlling the access to the DNA template, by regulating the rate of transcription elongation, and by modulating the level of gene expression.

Pol I has been identified as a potential drug target and a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. One of the main reasons for its potential as a drug target is its involvement in the regulation of gene expression, which makes it an attractive target for small molecules that can modulate gene expression.

Another reason for its potential as a biomarker is its role in the regulation of cell growth and differentiation. Pol I is involved in the regulation of cell growth and differentiation by controlling the access to the DNA template and by regulating the rate of transcription elongation. This makes it an attractive target for small molecules that can modulate cell growth and differentiation.

In conclusion, RNA polymerase I complex (Pol I) is a protein that plays a crucial role in the process of transcription in the cell. It is composed of multiple subunits that are responsible for catalyzing the synthesis of RNA from DNA template. Pol I is involved in the regulation of gene expression by controlling the access to the DNA template and by regulating the rate of transcription elongation. It is potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases due to its involvement in the regulation of gene expression and cell growth and differentiation.

Protein Name: RNA Polymerase I Complex

The "RNA Polymerase I Complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA Polymerase I Complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets